1. Impact of biological therapies on clinical outcomes in patients with severe eosinophilic asthma with chronic rhinosinusitis: an observational study from Saudi Arabia
- Author
-
Usama E. Abuelhassan, Abdelrahman M. Abdalla, Abdulaziz Alfaifi, Sultan K. Kadasah, Mohammed A. Alshehri, Haneen A. Alasiri, Salihah Y. Al-Mani, Ali S. Kadasah, Abdullah Musleh, Fawwaz A. Alshafa, Muhammad S. S. Qureshi, Abdulmohsen Y. Assiri, Abdulrahman I. Falqi, Bader I. Asiri, Haider M. O. Ahmed, Saleem Alshehri, Fasih U. Rahman, Muhammad A. Qureshi, Omar Abdelwahab, Sherif Mohamed, Ahmed R. I. Ali, Saad M. A. Alqahtani, and Medhat Elnamaky
- Subjects
Outcomes ,Clinical ,Severe asthma ,Rhinosinusitis ,Saudi Arabia ,ACT ,Diseases of the respiratory system ,RC705-779 ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract Background We aimed to study the impact of biological therapies in Saudi Arabia on patients with severe asthma (SA) combined with chronic rhinosinusitis (CRS) in terms of clinical outcomes. Methods This is a retrospective observational cohort research that was undertaken at the severe asthma clinics of the Armed Forces Hospital of the Southern Region (AFHSR) and King Khalid University Hospital, Abha, from March to September 2022 to delineate the effects of 3 biological therapies (dupilumab, benralizumab, and omalizumab) in adults with SA and concomitant CRS. Clinical outcomes assessed included asthma exacerbation frequency, hospitalization rates, use of oral corticosteroids (OCs), and the asthma control test (ACT) scores before and 1 year after biological therapies. Results Eighty patients were enrolled, with a mean age of 46.68. There were 45 (56%) females and 35 (44%) males. There was a notifiable decrease in the frequency of exacerbations and hospitalization and in the number of patients who received OCs after 6 and 12 months of biological therapies compared to pre-biological therapies, respectively (p
- Published
- 2024
- Full Text
- View/download PDF